Pneumocandin B0

• CAT Number: I001378
• CAS Number: 135575-42-7
• Molecular Formula: C50H80N8O17
• Molecular Weight: 1065.20
• Purity: ≥95%
• Synonyms: L 688786; L688786; L-688786
• Solubility: 10 mM in DMSO
• Storage: -20°C
• IUPAC Name: (10R,12S)-N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S)-3-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide
• InChI: InChI=1S/C50H80N8O17/c1-5-25(2)20-26(3)12-10-8-6-7-9-11-13-37(66)52-31-22-35(64)46(71)56-48(73)41-33(62)18-19-57(41)50(75)39(34(63)23-36(51)65)54-47(72)40(43(68)42(67)28-14-16-29(60)17-15-28)55-45(70)32-21-30(61)24-58(32)49(74)38(27(4)59)53-44(31)69/h14-17,25-27,30-35,38-43,46,59-64,67-68,71H,5-13,18-24H2,1-4H3,(H2,51,65)(H,52,66)(H,53,69)(H,54,72)(H,55,70)(H,56,73)/t25-,26+,27+,30+,31-,32-,33-,34+,35+,38-,39-,40-,41-,42-,43-,46+/m0/s1
• InChIKey: DQXPFAADCTZLNL-FXDJFZINSA-N
• SMILES: CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@@H](CC(=O)N)O)O)O)O

Pneumocandin B0 (Cat No.:I001378) is a lipopeptide antifungal agent belonging to the echinocandin class. It is derived from the fermentation of the fungus Glarea lozoyensis. Pneumocandin B0 inhibits the synthesis of beta-(1,3)-D-glucan, an essential component of the fungal cell wall. By targeting this key component, it disrupts the integrity and function of the fungal cell wall, leading to cell lysis and ultimately the death of the fungal cells. Pneumocandin B0 is primarily used as a therapeutic agent for the treatment of invasive fungal infections, particularly those caused by Candida species. Its mechanism of action and specificity for fungal cells make it an effective and important tool in the management of serious fungal infections.

Reference

1: Zhang L, Zhang H, Li L, Zuo P, Zhao F, Liu M, Ye BC, Li Y. Pneumocandin
B0-imprinted Polymer Using Surface-imprinting Technique for Efficient
Purification of Crude Product. Anal Sci. 2016;32(9):923-30. doi:
10.2116/analsci.32.923. PubMed PMID: 27682395.
2: Leonard WR Jr, Belyk KM, Conlon DA, Bender DR, DiMichele LM, Liu J, Hughes DL.
Synthesis of the antifungal beta-1,3-glucan synthase inhibitor CANCIDAS
(caspofungin acetate) from pneumocandin B0. J Org Chem. 2007 Mar
30;72(7):2335-43. Epub 2007 Mar 8. PubMed PMID: 17343416.
3: Chen L, Yue Q, Li Y, Niu X, Xiang M, Wang W, Bills GF, Liu X, An Z.
Engineering of Glarea lozoyensis for exclusive production of the pneumocandin B0
precursor of the antifungal drug caspofungin acetate. Appl Environ Microbiol.
2015 Mar;81(5):1550-8. doi: 10.1128/AEM.03256-14. Epub 2014 Dec 19. PubMed PMID:
25527531; PubMed Central PMCID: PMC4325176.
4: Welch CJ, DaSilva JO, Nti-Gyabaah J, Antia F, Goklen K, Boyd R. Preparation
and evaluation of novel stationary phases for improved chromatographic
purification of pneumocandin B0. J Chromatogr A. 2006 Jan 6;1101(1-2):204-13.
Epub 2005 Oct 27. PubMed PMID: 16257000.
5: Leonard WR Jr, Belyk KM, Bender DR, Conlon DA, Hughes DL, Reider PJ.
Determination of the relative and absolute configuration of the dimethylmyristoyl
side chain of pneumocandin B0 by asymmetric synthesis. Org Lett. 2002 Nov
28;4(24):4201-4. PubMed PMID: 12443058.